Two new drugs for advanced pancreatic cancer
Part of Cancer clinical trials.
This study tests two new drugs (cosibelimab and balixafortide) given together to see if they can help people with advanced pancreatic cancer that has not responded to standard chemotherapy. The goal is to find a safe and effective treatment option for this difficult-to-treat cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have advanced pancreatic cancer that has spread or cannot be surgically removed, and it must have progressed after standard chemotherapy.
- You must have a performance status (ECOG) of 0-2, meaning you are generally able to care for yourself, though you may need some help.
- You must not have had prior treatment with certain immunotherapy drugs (like PD-1, PD-L1, or CTLA-4 inhibitors).
- You must not have active or recent lung inflammation that required steroids, and no active autoimmune disease requiring immunosuppressive treatment in the past 2 years.
- You must not have untreated brain metastases, active infections, or have received a live vaccine within 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing two immunotherapy drugs (balstilimab and botensilimab) to see if they can shrink tumors in people with advanced pancreatic cancer that has worsened after at least one prior treatment. If you have microsatellite stable (MSS) disease, you may be eligible.
This trial tests a new combination of drugs (TQB2868 injection plus anlotinib capsules) compared to standard chemotherapy for people with pancreatic cancer that has spread to other parts of the body and has not been treated before.
This trial tests a combination of three drugs (serplulimab, bevacizumab, and a chemotherapy regimen) for people with pancreatic cancer that has spread or cannot be removed. It is for those who have already had one prior treatment and aims to see if this new combination can help control the cancer.
This trial tests a new targeted drug, telisotuzumab adizutecan, combined with standard chemotherapy (FOLFOX) for people with advanced pancreatic cancer that has spread. The goal is to see if this combination works better than current treatments.
This study tests whether combining three treatments—NALIRIFOX (chemotherapy), Adebrelimab (an immune-boosting antibody), and PULSAR (radiation)—can help people with advanced pancreatic cancer that hasn't been treated before. The goal is to see if this combination works better than standard care.
This study tests a new treatment for people with stage 4 pancreatic cancer who haven't yet had any treatment for advanced disease. The goal is to see if the new treatment can help shrink or control the cancer.
Hear when a new Metastatic Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.